Financing ·
First Tracks Biotherapeutics prices $200M private placement of common stock at $32.75 per share
TRAXFirst Tracks Biotherapeutics, Inc.
First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 shares of common stock to institutional investors in a private placement priced at $32.75 per share. The transaction is expected to generate approximately $200 million in gross proceeds before fees and expenses. Closing is anticipated on October 19, 2026, subject to customary conditions. Proceeds will fund general corporate purposes, including clinical development of ANB033. Investors include Affinity Asset Advisors, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, and Vestal Point Capital. Placement agents are Leerink Partners, Piper Sandler, UBS Investment Bank, and Wells Fargo Securities. First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies that modulate immune pathways implicated in autoimmune and inflammatory diseases.